In today's fast-paced technological advancements in medicine, the treatment of acute bacterial skin and skin structure ...

Basilea will seek approval of ceftobiprole for SAB as well as acute bacterial skin and skin structure infection (ABSSSI) based on the results of the earlier TARGET study which showed non ...

for the treatment of acute bacterial skin and soft structure infections (ABSSSIs) and community-acquired pneumonia. In 2010, the FDA specified a new primary end point for ABSSSI of 3 days instead ...

The patients all had some form of acute bacterial skin and skin structure infections (ABSSSI), including some with diabetic foot infections. R327G was also shown to be safe and well tolerated ...

The Australian company’s open-label trial of Recce 327, a topical treatment designed to treat acute bacterial skin and skin structure infections (ABSSSI) and diabetic foot infections (DFIs ...

Recce said the study would progress to a registrational phase 3 in acute bacterial skin and skin structure infections (ABSSSI) and diabetic foot infections (DFIs). The developer of a new class of ...

SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was ...

StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a hold rating on the ...

The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic ...